These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 34724432)

  • 1. Estimating The Appropriate Size Of Global Pull Incentives For Antibacterial Medicines.
    Outterson K
    Health Aff (Millwood); 2021 Nov; 40(11):1758-1765. PubMed ID: 34724432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pull Incentives for Antibacterial Drug Development: An Analysis by the Transatlantic Task Force on Antimicrobial Resistance.
    Årdal C; Røttingen JA; Opalska A; Van Hengel AJ; Larsen J
    Clin Infect Dis; 2017 Oct; 65(8):1378-1382. PubMed ID: 29017240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reimbursement models to tackle market failures for antimicrobials: Approaches taken in France, Germany, Sweden, the United Kingdom, and the United States.
    Gotham D; Moja L; van der Heijden M; Paulin S; Smith I; Beyer P
    Health Policy; 2021 Mar; 125(3):296-306. PubMed ID: 33402265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. To Push or To Pull? In a Post-COVID World, Supporting and Incentivizing Antimicrobial Drug Development Must Become a Governmental Priority.
    Cama J; Leszczynski R; Tang PK; Khalid A; Lok V; Dowson CG; Ebata A
    ACS Infect Dis; 2021 Aug; 7(8):2029-2042. PubMed ID: 33606496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic Incentives for Antibacterial Drug Development: Literature Review and Considerations From the Transatlantic Task Force on Antimicrobial Resistance.
    Sciarretta K; Røttingen JA; Opalska A; Van Hengel AJ; Larsen J
    Clin Infect Dis; 2016 Dec; 63(11):1470-1474. PubMed ID: 27578820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can the UK 'Netflix' Payment Model Boost the Antibacterial Pipeline?
    Leonard C; Crabb N; Glover D; Cooper S; Bouvy J; Wobbe M; Perkins M
    Appl Health Econ Health Policy; 2023 May; 21(3):365-372. PubMed ID: 36646872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Global Pull Incentives for Better Antibacterials: The UK Leads the Way.
    Outterson K; Rex JH
    Appl Health Econ Health Policy; 2023 May; 21(3):361-364. PubMed ID: 36773115
    [No Abstract]   [Full Text] [Related]  

  • 8. Evaluating for-profit public benefit corporations as an additional structure for antibiotic development and commercialization.
    Outterson K; Rex JH
    Transl Res; 2020 Jun; 220():182-190. PubMed ID: 32165059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient Access in 14 High-Income Countries to New Antibacterials Approved by the US Food and Drug Administration, European Medicines Agency, Japanese Pharmaceuticals and Medical Devices Agency, or Health Canada, 2010-2020.
    Outterson K; Orubu ESF; Rex J; Årdal C; Zaman MH
    Clin Infect Dis; 2022 Apr; 74(7):1183-1190. PubMed ID: 34251436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Past, Present, and Future of Antibacterial Economics: Increasing Bacterial Resistance, Limited Antibiotic Pipeline, and Societal Implications.
    Luepke KH; Suda KJ; Boucher H; Russo RL; Bonney MW; Hunt TD; Mohr JF
    Pharmacotherapy; 2017 Jan; 37(1):71-84. PubMed ID: 27859453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systems, not pills: The options market for antibiotics seeks to rejuvenate the antibiotic pipeline.
    Brogan DM; Mossialos E
    Soc Sci Med; 2016 Feb; 151():167-72. PubMed ID: 26808335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective antibacterials: at what cost? The economics of antibacterial resistance and its control.
    White AR;
    J Antimicrob Chemother; 2011 Sep; 66(9):1948-53. PubMed ID: 21700625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pull incentives for antibiotics get push from the UK.
    Mullard A
    Nat Rev Drug Discov; 2022 Jun; 21(6):406. PubMed ID: 35538235
    [No Abstract]   [Full Text] [Related]  

  • 14. CNS drug development in Europe--past progress and future challenges.
    Nutt DJ; Attridge J
    Neurobiol Dis; 2014 Jan; 61():6-20. PubMed ID: 23685094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implementation of a Market Entry Reward within the United States.
    Daniel GW; Schneider M; Lopez MH; McClellan MB
    J Law Med Ethics; 2018 Jun; 46(1_suppl):50-58. PubMed ID: 30146957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Financing Pull Mechanisms for Antibiotic-Related Innovation: Opportunities for Europe.
    Årdal C; Lacotte Y; Ploy MC
    Clin Infect Dis; 2020 Nov; 71(8):1994-1999. PubMed ID: 32060511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Broken Antibiotic Market: Review of Strategies to Incentivize Drug Development.
    Bhavnani SM; Krause KM; Ambrose PG
    Open Forum Infect Dis; 2020 Jul; 7(7):ofaa083. PubMed ID: 32667365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promoting Antibacterial Drug Development: Select Policies and Challenges.
    Sertkaya A; Jessup A; Wong HH
    Appl Health Econ Health Policy; 2017 Feb; 15(1):113-118. PubMed ID: 27601239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Market concentration of new antibiotic sales.
    Rahman S; Lindahl O; Morel CM; Hollis A
    J Antibiot (Tokyo); 2021 Jun; 74(6):421-423. PubMed ID: 33664435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New business models for antibiotic innovation.
    So AD; Shah TA
    Ups J Med Sci; 2014 May; 119(2):176-80. PubMed ID: 24646116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.